Stock TNFA TNF PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

TNF Pharmaceuticals, Inc. Stock

Equities

TNFA

US62856X2018

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-12-13 pm EST 		5-day change 1st Jan Change
1.150 USD -3.36% Intraday chart for TNF Pharmaceuticals, Inc. -7.26% -85.18%
Nov. 14 TNF Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
Oct. 02 TNF Pharmaceuticals Secures Strategic Investment From Prevail Partners; Shares Rise MT

Valuation: TNF Pharmaceuticals, Inc.

Capitalization 3.17M 3.02M 2.83M 2.51M 4.51M 269M 4.99M 34.8M 12.87M 111M 11.9M 11.64M 487M P/E ratio 2022
-2.94x
P/E ratio 2023 -1.46x
Enterprise value -1.71M -1.63M -1.52M -1.35M -2.43M -145M -2.68M -18.74M -6.93M -59.62M -6.41M -6.27M -262M EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
94.88%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data

Chart: TNF Pharmaceuticals, Inc.

Dynamic Chart

Latest news: TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 14 CI
TNF Pharmaceuticals Secures Strategic Investment From Prevail Partners; Shares Rise Oct. 02 MT
TNF Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Prevail Partners Sep. 30 CI
Top Premarket Decliners Sep. 26 MT
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline Aug. 21 CI
TNF Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Aug. 19 CI
MyMD Pharmaceuticals, Inc. will Change its Ticker to TNFA from MYMD Jul. 24 CI
MyMD Pharmaceuticals Rebrands to TNF Pharmaceuticals; Trading Under New Symbol to Begin Wednesday Jul. 22 MT
MyMD Pharmaceuticals, Inc. has Changed its Name to TNF Pharmaceuticals, Inc Jul. 22 CI
MyMD Pharmaceuticals, Inc. Announces Management Changes Jun. 17 CI
TNF Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc. Jun. 16 CI
TNF Pharmaceuticals, Inc. amended terms of the transaction May. 22 CI
TNF Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc. May. 19 CI
More news

Press Releases: TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference Dec. 09 BU
TNF Pharmaceuticals : Announces Strategic Equity Investment Priced at a Premium to Market Form 8 K Oct. 07 PU
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market Oct. 02 BU
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline Aug. 21 BU
TNF Pharmaceuticals : MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc Form 8 K Jul. 26 PU
More press releases

Quotes and Performance

1 day-3.36%
1 week-7.26%
Current month+1.77%
1 month-8.00%
3 months-12.88%
6 months-47.25%
Current year-85.18%
More quotes

Course Extremes

1 week
1.05
Extreme 1.05
1.64
1 month
1.05
Extreme 1.05
1.64
Current year
1.05
Extreme 1.05
8.70
1 year
1.05
Extreme 1.05
10.67
3 years
1.05
Extreme 1.05
209.40
5 years
1.05
Extreme 1.05
298.50
10 years
1.05
Extreme 1.05
298.50
More quotes

Managers and Directors: TNF Pharmaceuticals, Inc.

Director TitleAgeSince
Mitchell Glass PSD
 President 73 2024-06-13
Ian Rhodes DFI
 Director of Finance/CFO 51 2021-04-14
Robert Schatz IRC
 Investor Relations Contact - -
Manager TitleAgeSince
Joshua Silverman CHM
 Chairman 55 -
Bill White BRD
 Director/Board Member 64 2017-08-07
Craig Eagle BRD
 Director/Board Member 57 2021-04-15
More insiders

ETFs: TNF Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
VANGUARD US TOTAL MARKET SHARES INDEX ETF ETF Vanguard US Total Market Shares Index ETF
0.00% 293,477 M€ +35.26% -
More ETFs: TNF Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
TNF PHARMACEUTICALS, INC. Stock TNF Pharmaceuticals, Inc.
-3.36%-7.26%-85.40%-99.44%3.17M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.08%+0.35%+14.48%+122.79%119B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
-1.31%-6.00%-16.53%+10.78%78.68B
ARGENX SE Stock argenx SE
-0.14%-1.69%+36.31%+117.61%36.8B
BIONTECH SE Stock BioNTech SE
-0.26%-1.10%+23.87%-56.73%28.86B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-1.03%+2.32%-23.68%-58.23%22.22B
BEIGENE, LTD. Stock BeiGene, Ltd.
-0.51%-12.78%-2.17%-36.61%19.06B
GENMAB A/S Stock Genmab A/S
-3.33%-7.13%-32.87%-42.44%12.86B
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
-0.22%-3.83%+661.97%+277.75%13.15B
INSMED INCORPORATED Stock Insmed Incorporated
-0.58%-5.00%+149.49%+165.79%12.81B
Average -1.08%-4.62%+72.55%+40.13% 34.39B
Weighted average by Cap. -0.61%-2.53%+35.14%+62.36%
See all sector performances

Financials

2022 2023
Net sales - -
Net income -15.2M -14.48M -13.58M -12.04M -21.64M -1.29B -23.91M -167M -61.74M -531M -57.1M -55.82M -2.34B -4M -3.81M -3.57M -3.17M -5.69M -339M -6.29M -43.94M -16.25M -140M -15.03M -14.69M -615M
Net Debt -4.69M -4.47M -4.19M -3.72M -6.68M -398M -7.39M -51.57M -19.07M -164M -17.64M -17.24M -721M -4.87M -4.64M -4.35M -3.86M -6.94M -413M -7.67M -53.54M -19.8M -170M -18.31M -17.9M -749M
More financial data * Estimated data

Company Profile

Logo TNF Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Employees
6
Sector
Biotechnology & Medical Research
More about the company

Quotes

Date Price Change Volume
24-12-13 1.150 $ -3.36% 151,290
24-12-12 1.190 $ -2.46% 109,068
24-12-11 1.220 $ -22.29% 440,947
24-12-10 1.570 $ +11.35% 1,372,943
24-12-09 1.410 $ +13.71% 992,946

Delayed Quote Nasdaq, December 13, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart TNF-PHARMACEUTICALS-INC More financial data
  1. Stock Market
  2. Equities
  3. TNFA Stock